The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being ...

The primary outcome was the GBS-DS at 8 weeks. The GBS-DS is a 7-point scale, but at the request of the FDA, Allen said, it was collapsed into a 3-point scale for this analysis. Scores of 0 and 1 ...

Patients treated with tanruprubart were approximately three times more likely to be in a better state of health than patients on IVIg or PE on the GBS-Disability Scale (GBS-DS) at Weeks 4, 8, and 26 ...

GBS is a rare disorder where the immune system attacks nerve cells, causing paralysis.

Pune authorities are investigating 22 suspected cases of Guillain-Barré syndrome (GBS), a rare neurological disorder, mainly affecting people aged 12 to 30. While the cases are spread across ...

Results from a phase 2 clinical trial showed that treatment with an IgG-cleaving enzyme for individuals diagnosed with Guillain-Barré syndrome led to faster muscle strength recovery and mobility ...

GBS also empowers student enterprise through a dedicated Entrepreneurship Team and an Enterprise Hub, helping students either launch new businesses or scale up existing ones.

Kochi: The first GBS death was on Tuesday reported in Kerala after a 58-year-old died of Guillain-Barre Syndrome in Kochi. The patient was undergoing treatment in Kottayam Medical College.

The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being ...

The primary outcome was the GBS-DS at 8 weeks. The GBS-DS is a 7-point scale, but at the request of the FDA, Allen said, it was collapsed into a 3-point scale for this analysis.